PDCD1 and neoplasm: Blockade of programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) immune checkpoints by monoclonal antibodies has shown measurable success in cancer therapy against a variety of tumor types, including non–small-cell lung cancer (NSCLC) [1,2].